Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Valenta

Showing results (221-230 of 287) with videos related to

Pageof 29
Sort By:
Pneumologie (Stuttgart, Germany)|September 1, 1996
[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]G Menz, C Dolecek, U Schönheit-Kenn, et al.
The Journal of Allergy and Clinical Immunology|September 7, 2001
A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgES Laffer, E Hogbom, K H Roux, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 20, 2008
Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesA Purohit, V Niederberger, M Kronqvist, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 15, 2004
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1V Mahler, S Vrtala, O Kuss, et al.
Molecular Immunology|February 22, 2008
Isolation, expression and immunological characterization of a calcium-binding protein from Parietaria pollenA Bonura, L Gulino, A Trapani, et al.
International Journal of Immunopathology and Pharmacology|March 14, 2008
Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patientsK Sonneck, C Baumgartner, L Rebuzzi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 11, 2007
Detection of an allergen in dog dander that cross-reacts with the major cat allergen, Fel d 1R Reininger, E M Varga, M Zach, et al.
The Journal of Allergy and Clinical Immunology|March 1, 1997
Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollenJ Godnic-Cvar, M Susani, H Breiteneder, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 6, 2003
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodiesN Mothes, M Heinzkill, K J Drachenberg, et al.
Allergy|January 11, 2018
Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE cross-reactivityM Curin, T Garmatiuk, Y Resch-Marat, et al.
Pageof 29

Showing results (221-230 of 287) with videos related to

Sort By:
Pageof 29
Pneumologie (Stuttgart, Germany)|September 1, 1996
[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch]G Menz, C Dolecek, U Schönheit-Kenn, et al.
The Journal of Allergy and Clinical Immunology|September 7, 2001
A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgES Laffer, E Hogbom, K H Roux, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 20, 2008
Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesA Purohit, V Niederberger, M Kronqvist, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 15, 2004
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1V Mahler, S Vrtala, O Kuss, et al.
Molecular Immunology|February 22, 2008
Isolation, expression and immunological characterization of a calcium-binding protein from Parietaria pollenA Bonura, L Gulino, A Trapani, et al.
International Journal of Immunopathology and Pharmacology|March 14, 2008
Recombinant allergens promote expression of aminopeptidase-n (CD13) on basophils in allergic patientsK Sonneck, C Baumgartner, L Rebuzzi, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 11, 2007
Detection of an allergen in dog dander that cross-reacts with the major cat allergen, Fel d 1R Reininger, E M Varga, M Zach, et al.
The Journal of Allergy and Clinical Immunology|March 1, 1997
Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollenJ Godnic-Cvar, M Susani, H Breiteneder, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 6, 2003
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodiesN Mothes, M Heinzkill, K J Drachenberg, et al.
Allergy|January 11, 2018
Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE cross-reactivityM Curin, T Garmatiuk, Y Resch-Marat, et al.
Pageof 29